| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2015 | WO2015025528A1 Novel mangromicin compound and free radical scavenger comprising same |
| 02/26/2015 | WO2015025326A1 3-(4-ethynylphenyl) pyridopyrimidinone compounds and process for preparation thereof useful as potential antic ancer agents |
| 02/26/2015 | WO2015025312A1 Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
| 02/26/2015 | WO2015025294A1 Catechin for treating renal lithiasis |
| 02/26/2015 | WO2015025261A1 Duloxetine enteric coated tablet |
| 02/26/2015 | WO2015025259A1 Indole-3-aldehyde for treating dysreactive immune disorders |
| 02/26/2015 | WO2015025228A2 Compositions and therapeutic methods for accelerated plaque regression |
| 02/26/2015 | WO2015025226A2 Compositions and therapeutic methods for accelerated plaque regression |
| 02/26/2015 | WO2015025180A1 Cholesterol modulation |
| 02/26/2015 | WO2015025172A1 5-aryl-thiazol-2-yl-amine compounds and their therapeutic use |
| 02/26/2015 | WO2015025164A1 Amide derivatives as lysophosphatidic acid receptor antagonists |
| 02/26/2015 | WO2015025119A1 Topical drug patch including microspheres |
| 02/26/2015 | WO2015025061A1 Compounds and formulations for the treatment of wounds |
| 02/26/2015 | WO2015025026A1 Alkynyl alcohols and methods of use |
| 02/26/2015 | WO2015025025A1 Alkynyl alcohols and methods of use |
| 02/26/2015 | WO2015024992A2 Treatment of asthma |
| 02/26/2015 | WO2015024986A1 INHIBITION OF A lncRNA FOR TREATMENT OF MELANOMA |
| 02/26/2015 | WO2015024925A1 Modulators of the unconventional secretory pathway for use in the treatment of alexander disease |
| 02/26/2015 | WO2015024905A1 Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders |
| 02/26/2015 | WO2015024884A1 Method for the purifiction of epothilones via crystallization |
| 02/26/2015 | WO2015024883A1 Method for the purification of epothilones via crystallization |
| 02/26/2015 | WO2015024878A1 Novel neurokinin 1 receptor antagonist compounds ii |
| 02/26/2015 | WO2015024876A2 Screening method |
| 02/26/2015 | WO2015024819A1 V1a antagonists to treat phase shift sleep disorders |
| 02/26/2015 | WO2015024526A1 Carboxylic acid compounds in treatment of diabetes mellitus |
| 02/26/2015 | WO2015024512A1 Use of icaritin in preparation of drugs for treatment of diseases related to flt-3 |
| 02/26/2015 | WO2015024486A1 Dgat1 inhibitor and preparation method and use thereof |
| 02/26/2015 | WO2015024448A1 Benzo piperidine ring and benzo morpholine ring compounds, manufacturing method therefor, and medical applications thereof |
| 02/26/2015 | WO2015024420A1 Local anesthesia pain-relieving time-delay agent |
| 02/26/2015 | WO2015024298A1 Macrolide compound |
| 02/26/2015 | WO2015024218A1 Pharmaceutical composition, preparation method therefor and use thereof |
| 02/26/2015 | WO2015024217A1 Chlorogenic acid powder-injection and preparation method thereof |
| 02/26/2015 | WO2015024203A1 Novel neurokinin 1 receptor antagonist compounds ii |
| 02/26/2015 | WO2015024111A1 Compounds for the treatment of hormone-dependent diseases |
| 02/26/2015 | WO2015024100A1 Non-anesthetic protective gases in combination with liquid anesthetic agents for organ protection |
| 02/26/2015 | WO2015024055A1 Separation of omega-3 fatty acids |
| 02/26/2015 | US20150057617 Anti-microbial dressing, an anti-microbial composition and use thereof |
| 02/26/2015 | US20150057486 Compositions and methods for sensitizing a neoplastic cell to radiation |
| 02/26/2015 | US20150057366 Synthesis of elemicin and topical analgesic compositions |
| 02/26/2015 | US20150057365 Gene expression regulating agent |
| 02/26/2015 | US20150057364 Cleanser compositions and methods for using the same |
| 02/26/2015 | US20150057363 Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| 02/26/2015 | US20150057362 Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition |
| 02/26/2015 | US20150057361 Anti-metastatic agents predicated upon polyamine macrocyclic conjugates |
| 02/26/2015 | US20150057360 Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| 02/26/2015 | US20150057359 Methods of colchicine administration |
| 02/26/2015 | US20150057358 Novel sustained release dosage forms |
| 02/26/2015 | US20150057357 Bis (thiohydrazide amide) compounds for treating cancers |
| 02/26/2015 | US20150057356 Melt-extruded composition comprising a cellulose ether |
| 02/26/2015 | US20150057355 Amantadine compositions and methods of use |
| 02/26/2015 | US20150057354 Method of maintaining or improving tactical performance and cognitive function through dietary supplementation |
| 02/26/2015 | US20150057353 production of ultrapure EPA and polar lipids form largely heterotrophic culture |
| 02/26/2015 | US20150057352 Microorganisms, Compositions, and Methods for Producing Fatty Acids |
| 02/26/2015 | US20150057350 Fibrosis biomarkers and methods of using same |
| 02/26/2015 | US20150057349 4-oxo-2-pentenoic acid and the health of the digestive tract |
| 02/26/2015 | US20150057348 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof |
| 02/26/2015 | US20150057347 Compositions and methods for the treatment of inflammation and lipid disorders |
| 02/26/2015 | US20150057346 Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject |
| 02/26/2015 | US20150057344 Peltatin for the treatment of chronic inflammatory disorders |
| 02/26/2015 | US20150057343 AGONISTS OF THE AhR RECEPTOR PATHWAY HAVING SEBOSUPPRESSIVE ACTIVITY AND A METHOD FOR IDENTIFYING SAID AGONISTS |
| 02/26/2015 | US20150057342 Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
| 02/26/2015 | US20150057341 Composition with Pharmacological Effect for Vaporizing and Method |
| 02/26/2015 | US20150057335 Novel fusion genes identified in lung cancer |
| 02/26/2015 | US20150057333 Double-stranded oligonucleotides |
| 02/26/2015 | US20150057327 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 02/26/2015 | US20150057325 Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
| 02/26/2015 | US20150057324 Tablet containing 5-hydroxy-1h-imidazole-4-carboxamide |
| 02/26/2015 | US20150057323 Composition for treating ocular effects of diabetes |
| 02/26/2015 | US20150057321 Soft chewable pharmaceutical products |
| 02/26/2015 | US20150057320 Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular degeneration, stargardt disease, and other retinal disease characterized by excessive lipofuscin accumulation |
| 02/26/2015 | US20150057317 Gabr-a2 diagnostic |
| 02/26/2015 | US20150057314 Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| 02/26/2015 | US20150057313 Modulating afferent signals to treat medical conditions |
| 02/26/2015 | US20150057312 Substituted quinolines as bruton's tyrosine kinases inhibitors |
| 02/26/2015 | US20150057311 Heterocyclic GSK-3 Allosteric Modulators |
| 02/26/2015 | US20150057309 Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein, etc |
| 02/26/2015 | US20150057308 Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives |
| 02/26/2015 | US20150057306 Compositions comprising scopolamine and ketamine in the treatment of depression |
| 02/26/2015 | US20150057305 Pharmaceutical composition |
| 02/26/2015 | US20150057304 Extruded Immediate Release Abuse Deterrent Pill |
| 02/26/2015 | US20150057303 Synthesis of (r)-n-methylnaltrexone |
| 02/26/2015 | US20150057302 Spiroindoline compounds for use as anthelminthics |
| 02/26/2015 | US20150057296 Novel pharmaceutical dosage forms comprising valganciclovir hydrochloride |
| 02/26/2015 | US20150057293 New compounds |
| 02/26/2015 | US20150057290 Method of using flibanserin for neuroprotection |
| 02/26/2015 | US20150057287 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| 02/26/2015 | US20150057284 Method and improved pharmaceutical composition for enhancing transdermal delivery of pde-5 inhibitor |
| 02/26/2015 | US20150057281 Modulators of hec1 activity and methods therefor |
| 02/26/2015 | US20150057277 Certain chemical entities, compositions, and methods |
| 02/26/2015 | US20150057276 Certain chemical entities, compositions, and methods |
| 02/26/2015 | US20150057272 Benzimidazoles and related analogs as sirtuin modulators |
| 02/26/2015 | US20150057269 Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases |
| 02/26/2015 | US20150057267 Methods and Compositions for Treating Viral Diseases |
| 02/26/2015 | US20150057266 Pharmaceutical Composition Having Improved Dissolution Profiles For Poorly Soluble Drugs |
| 02/26/2015 | US20150057264 Bicyclic pyrazinone derivatives |
| 02/26/2015 | US20150057263 Quinazoline Compounds And Their Use In Therapy |
| 02/26/2015 | US20150057259 Stabilized compositions containing alkaline labile drugs |
| 02/26/2015 | US20150057258 4-pregenen-11beta-17-21-triol-3,20-dione derivatives |
| 02/26/2015 | US20150057257 Isoxazolidine derivatives |
| 02/26/2015 | US20150057256 Novel polymorphic crystal forms of 5-(2--1-(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisytlate as agonist of the beta2 adrenergic receptor |